Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)

Selina M Luger,Jerald P Radich,Steven D Gore,Amer M Zeidan,Vijaya R Bhatt,Mark Litzow,Elad Sharon,Victoria Wang,Jan Philipp Bewersdorf

doi:10.1182/blood-2020-137734

Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)

Selina M Luger, Jerald P Radich + Show 7 more

Open Access

https://doi.org/10.1182/blood-2020-137734

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 3

Affiliation: Cheyney University of Pennsylvania, University of Washington, Center for Cancer Research, Yale Cancer Center, University of Nebraska Medical Center, Mayo Clinic, National Cancer Institute, Harvard University Press, Yale University

#Undetectable Minimal Residual Disease #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)

Full Text